Current Valuation Metrics and Market Context
As of the latest trading session, Krishna Institute of Medical Sciences is priced at ₹684.75, showing a day change of 1.47% from the previous close of ₹674.85. The stock has traded within a range of ₹670.40 to ₹685.10 today, with a 52-week high of ₹798.00 and a low of ₹474.55. These price levels provide a backdrop for understanding the valuation shifts in the context of recent market movements.
The company’s price-to-earnings (P/E) ratio stands at 83.68, a figure that places it in the very expensive category when compared to its historical averages and sector peers. This metric indicates the price investors are willing to pay for each rupee of earnings, suggesting elevated expectations for future growth or profitability. The price-to-book value (P/BV) ratio is recorded at 12.07, further underscoring the premium valuation relative to the company’s net asset value.
Other valuation multiples include an enterprise value to EBIT (EV/EBIT) ratio of 53.92 and an enterprise value to EBITDA (EV/EBITDA) ratio of 38.97. These ratios provide insight into the company’s operating profitability relative to its enterprise value, signalling a market assessment that attributes significant value to Krishna Institute of Medical Sciences’ earnings before interest, taxes, depreciation, and amortisation.
Only 1% make it here. This Large Cap from the Gems, Jewellery And Watches sector passed our rigorous filters with flying colors. Be among the first few to spot this gem!
- - Highest rated stock selection
- - Multi-parameter screening cleared
- - Large Cap quality pick
Comparison with Industry Peers
When placed alongside other prominent companies in the hospital and healthcare sector, Krishna Institute of Medical Sciences’ valuation metrics reveal a nuanced picture. For instance, Aster DM Healthcare, categorised as expensive, holds a P/E ratio of 92.17 and an EV/EBITDA of 42.14, both higher than Krishna Institute’s respective figures. Dr Lal Pathlabs and Dr Agarwal’s Healthcare, both classified as very expensive, report P/E ratios of 48.65 and 188.53 respectively, with EV/EBITDA multiples of 33.61 and 36.62.
Other peers such as Rainbow Children’s and Vijaya Diagnostic Centre also fall into the very expensive category, with P/E ratios of 54.15 and 67.61 and EV/EBITDA multiples of 28.14 and 35.74 respectively. This comparison highlights that while Krishna Institute of Medical Sciences is positioned as very expensive, it is not an outlier within its peer group, where elevated valuation multiples are common.
Interestingly, Health.Global is marked as attractive despite a P/E ratio of 288.02, which suggests that valuation alone does not dictate market attractiveness but must be considered alongside growth prospects and other financial parameters.
Return Performance Relative to Sensex
Krishna Institute of Medical Sciences’ stock returns over various periods provide additional context to its valuation. Over the past week, the stock has returned 3.13%, outperforming the Sensex’s 0.50% return. However, over the last month, the stock recorded a negative return of 4.88%, contrasting with the Sensex’s positive 1.66% gain.
Year-to-date, the stock has delivered a 13.94% return, surpassing the Sensex’s 9.56%. Over the last year, the stock’s return of 14.51% also outpaces the benchmark’s 7.01%. Longer-term performance over three years shows a substantial 132.4% return for Krishna Institute of Medical Sciences, significantly exceeding the Sensex’s 37.43% return for the same period.
These figures suggest that despite the valuation premium, the stock has delivered returns that justify, to some extent, the market’s elevated expectations.
Holding Krishna Institute of Medical Sciences from Hospital? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Profitability and Efficiency Metrics
Krishna Institute of Medical Sciences reports a return on capital employed (ROCE) of 10.59% and a return on equity (ROE) of 14.42%. These profitability ratios provide insight into how effectively the company utilises its capital and equity base to generate earnings. While these figures are moderate, they are important considerations when evaluating the premium valuation multiples.
The enterprise value to capital employed (EV/CE) ratio is 5.71, and the enterprise value to sales (EV/Sales) ratio stands at 8.96. These metrics indicate the market’s valuation of the company relative to its capital base and revenue generation, respectively. The PEG ratio is noted as 0.00, which may reflect the absence of a meaningful growth rate input or an analytical adjustment in the evaluation.
Valuation Shifts and Market Implications
The recent revision in Krishna Institute of Medical Sciences’ evaluation metrics, moving from an expensive to a very expensive category, signals a shift in market assessment. This change suggests that investors are attributing a higher premium to the stock, potentially due to expectations of sustained growth, sector dynamics, or company-specific developments.
However, the elevated P/E and P/BV ratios also imply that the stock’s price incorporates significant optimism, which may increase sensitivity to earnings disappointments or sector headwinds. Investors should weigh these valuation levels against the company’s operational performance and broader market conditions.
Comparisons with peers reveal that while Krishna Institute of Medical Sciences is valued at a premium, it remains within the valuation spectrum observed in the hospital sector, where multiples tend to be elevated due to growth prospects and healthcare demand dynamics.
Given the stock’s historical return outperformance relative to the Sensex, the valuation premium may be partially justified. Nonetheless, the current market assessment adjustment invites a closer examination of future earnings trajectories and sector developments.
Conclusion
Krishna Institute of Medical Sciences’ recent valuation parameter changes reflect a market environment that favours premium pricing for hospital sector stocks with growth potential. The company’s P/E ratio of 83.68 and P/BV of 12.07 position it firmly in the very expensive category, consistent with sector peers exhibiting similar valuation profiles.
Investors should consider these valuation levels in conjunction with the company’s profitability metrics, return performance, and sector outlook. While the stock has delivered returns that exceed benchmark indices over multiple timeframes, the elevated valuation multiples suggest a need for careful monitoring of earnings growth and market conditions to assess ongoing attractiveness.
As the hospital sector continues to evolve, Krishna Institute of Medical Sciences remains a significant player whose market assessment adjustments warrant attention from investors seeking exposure to healthcare services.
Get 1 year of Weekly Picks FREE when you subscribe to MojoOne. Offer ends soon. Start Saving Now →
